Health Technology
Takeda Pharmaceutical Co., Ltd.
In the news
- Japan Inc says goodbye downtown, hello suburbs in post-pandemic era Jul 11, 2020
- Japan and Western drugmakers launch $1bn fund against superbugs Jul 10, 2020
- Japan execs' million-dollar club shrinks for first time in 8 years Jul 3, 2020
- Japan to ready 1m doses of coronavirus vaccine for swift distribution Jun 20, 2020
- Asia powerhouses in Q1: Sinopec stumbles but Nintendo thrives Jun 15, 2020 See more articles on Takeda Pharmaceutical Co., Ltd.
Business Summary
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.
Financial Highlights
| Mar 2020 | JPY | USD |
| Revenue | 3,291.18B | 30,270.54M |
| Gross Profit | 1,789.37B | 16,457.72M |
| Operating income | 302,612M | 2,783.25M |
| Income before tax | -60,754M | -558.78M |
| Net income | 44,241M | 406.90M |
| EBITDA | 886,261M | 8,151.34M |
| Diluted EPS | 28.24 | 0.25 |
| Dividends Per Share | 180 | 1.65 |
| Total Assets | 12,821.09B | 118,763.31M |
| Total liabilities | 8,093.60B | 74,972.05M |
| Total equity | 4,723.48B | 43,754.18M |
| Operating cash flow | 555,410M | 5,108.35M |
| Currency in JPY | Currency in USD |
Historical Data
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | |
| Revenue | 1,807.37B | 1,732.05B | 1,770.53B | 2,097.22B | 3,291.18B |
| Gross Profit | 1,161.84B | 1,017.65B | 1,148.86B | 1,275.55B | 1,789.37B |
| Operating income | 175,770M | 86,972M | 195,320M | 218,686M | 302,612M |
| Income before tax | 120,539M | 143,346M | 217,205M | 127,612M | -60,754M |
| Net income | 80,166M | 114,940M | 186,886M | 135,192M | 44,241M |
| EBITDA | 353,275M | 258,398M | 377,447M | 466,377M | 886,261M |
| Diluted EPS | 101.71 | 146.25 | 237.55 | 139.82 | 28.24 |
| Dividends Per Share | 180 | 180 | 180 | 180 | 180 |
| Total Assets | 3,824.08B | 4,346.79B | 4,106.46B | 13,792.77B | 12,821.09B |
| Total liabilities | 1,812.88B | 2,397.82B | 2,089.05B | 8,606.78B | 8,093.60B |
| Total equity | 1,948.69B | 1,894.26B | 1,997.42B | 5,181.98B | 4,723.48B |
| Operating cash flow | 26,552M | 260,067M | 379,600M | 302,609M | 555,410M |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | |
| Revenue | 15,050.91M | 15,994.93M | 15,974.84M | 18,911.85M | 30,270.54M |
| Gross Profit | 9,675.22M | 9,397.74M | 10,365.80M | 11,502.42M | 16,457.72M |
| Operating income | 1,463.72M | 803.15M | 1,762.30M | 1,972.01M | 2,783.25M |
| Income before tax | 1,003.78M | 1,323.75M | 1,959.76M | 1,150.74M | -558.78M |
| Net income | 667.58M | 1,061.43M | 1,686.20M | 1,219.10M | 406.90M |
| EBITDA | 2,941.89M | 2,386.22M | 3,405.56M | 4,205.58M | 8,151.34M |
| Diluted EPS | 0.84 | 1.35 | 2.14 | 1.26 | 0.25 |
| Dividends Per Share | 1.49 | 1.66 | 1.62 | 1.62 | 1.65 |
| Total Assets | 34,023.62M | 39,009.18M | 38,612.71M | 124,612.85M | 118,763.31M |
| Total liabilities | 16,129.56M | 21,518.70M | 19,643.19M | 77,759.25M | 74,972.05M |
| Total equity | 17,337.88M | 16,999.56M | 18,781.60M | 46,817.41M | 43,754.18M |
| Operating cash flow | 221.11M | 2,401.63M | 3,424.99M | 2,728.79M | 5,108.35M |
Valuation Measures
| Mar 2020 | |
| PER | 116.43 |
| ROA | 0.33% |
| ROE | 0.89% |
| Operating margin | 9.19% |
| Profit margin | 1.34% |
Key executives
- President, CEO & Representative Director: Christophe Weber
- Chief Financial Officer & Director: Constantine Saroukos
- Director, Research & Development President: Andrew S. Plump
- Chief Ethics & Compliance Officer: Mwana Lugogo
- Executive Officer & Global General Counsel: Yoshihiro Nakagawa
Shareholders
- Nomura Asset Management Co., Ltd. (3.7%)
- Sumitomo Mitsui Trust Asset Management Co., Ltd. (3.3%)
- BlackRock Fund Advisors (3.1%)
- The Vanguard Group, Inc. (2.6%)
- Nippon Life Insurance Co. (2.2%)
- Nikko Asset Management Co., Ltd. (1.5%)
- State Street Global Advisors Ltd. (1.5%)
- Capital Research & Management Co. (World Investors) (1.5%)
- Mondrian Investment Partners Ltd. (1.3%)
- Wellington Management Co. LLP (1.2%)
Contact Details
- Website:http://www.takeda.co.jp
- Address: 4-1-1 Dosho-machi, Chuo-Ku, Osaka, 540-8645, Japan
- Phone: +81.6.6204.2111
Related Companies
- Millennium Pharmaceuticals, Inc.
- Takeda Pharmaceutical Co. Ltd. /Europe OTC Portfolio/
- Plasmaspendedienst GmbH
- Gaido Health, Inc.
- Takeda Pharmaceutical Co. Ltd. /Non Core Latin America Assets/
- Takeda Pharmaceutical Co. Ltd. /Non Core Assets/
- Takeda Re Insurance AG
- Takeda Pharmaceutical Co. Ltd. /Tachosil Business/
- Plasmapunkt Favoriten GmbH
- Takeda Malaysia Sdn. Bhd.
- Takeda Pharmaceutical Co. Ltd. /Latam Bus/
- Takeda Oranienburg Real Estate GmbH & Co. KG
- Takeda Consumer Healthcare Co., Ltd.
- Pvp Biologics, Inc.
- Takeda Pharmaceutical Director Incentive Plan
- Takeda Pharmaceutical Employee Incentive Plan
- Oy Leiras Takeda Pharmaceuticals AB
- Takeda Architectural Design Consulting (Shanghai) Co. Ltd.
- Takeda Pharma AB
- Takeda Development Center Americas, Inc.
- Takeda Ukraine LLC
- Takeda Pharmaceuticals Taiwan Ltd.
- Takeda SRL
- Takeda Hellas SA
- Takeda Christiaens SCA/CVA
- Takeda Belgium SCA/CVA
- Takeda Vaccines Pte Ltd.
- Takeda Pharmaceuticals (Asia Pacific) Pte Ltd.
- Takeda Development Center Asia Pte Ltd.
- Takeda Pharma Sp zoo
Competitors
- AstraZeneca PLC
- Grifols, S.A. Class A
- Amgen Inc.
- Roche Holding AG
- Amicus Therapeutics, Inc.
- Protalix Biotherapeutics, Inc.
- Pfizer Inc.
- Novartis AG
- Sanofi
- Merck & Co., Inc.
- AbbVie, Inc.
- Johnson & Johnson
- CSL Limited
- Bristol-Myers Squibb Company
- Bayer AG
- Biotest AG Pref
- UCB S.A.
- Merck KGaA
- Swedish Orphan Biovitrum AB
- Novo Nordisk A/S Class B
- ISU Abxis Co., Ltd.
- Emmaus Life Sciences, Inc.
- Dr. Reddy's Laboratories Ltd.
- Hypera S.A.
- Ipsen SA
- Eli Lilly and Company
- Green Cross Holdings Corporation
- Daewoong Co., Ltd.
- BeiGene, Ltd.
- Hanmi Pharmaceutical Co., Ltd.
Copyright © 2020 FactSet Research Systems Inc. All rights reserved.
Last Updated on 3 Aug, 2020